article thumbnail

Introducing the Borderline Personality Disorder Inventory

Psychiatric Times

Knoll IV, MD November 19th 2024 4 Ways to Cope With Bipolar Uncertainty James Phelps, MD September 19th 2024 Borderline Personality Disorder and Complex Posttraumatic Stress Disorder: Myths in Diagnosis Mark L.

article thumbnail

Burnout, Boundaries and Balance

National Council for Mental Wellbeing (NCMW - the

In 2024, I was offered a role in a community mental health setting in middle Georgia by a former supervisor I had built a strong rapport with during my master’s program. But it didn’t take long for that kind of work to feel hollow. I missed feeling connected to something meaningful, to the communities I had served.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Stimulants Do Not Cause Psychosis: New Research

ADDitude

2024-069142. 2024 Oct 1;181(10):901-909. Epub 2024 Sep 12. Pediatrics. 2025 Jun 1;155(6):e2024069142. doi: 10.1542/peds.2024-069142. PMID: 40350165. 2 Moran LV, Skinner JP, Shinn AK, Nielsen K, Rao V, Taylor ST, Cohen TR, Erkol C, Merchant J, Mujica CA, Perlis RH, Ongur D. Am J Psychiatry. doi: 10.1176/appi.ajp.20230329.

article thumbnail

Exploding Myths About Schizophrenia: An Interview with Courtenay Harding

Mad in America

In 2024, she published a book, Recovery from Schizophrenia: Evidence, History and Hope , that told of her Vermont Longitudinal Study and how many in psychiatry, rather than celebrate the relatively good outcomes for the patients in her study, instead were quite furious with her for upsetting their beliefs.

article thumbnail

sNDA Submitted: Lumateperone for the Prevention of Relapse in Schizophrenia

Psychiatric Times

An sNDA for Caplyta as an adjunctive treatment for adults with major depressive disorder (MDD) is also currently under FDA review, submitted back in December 2024. December 3, 2024. The most commonly reported adverse events were somnolence/sedation, dizziness, nausea, and dry mouth. points (effect size 0.61) in study 501 and 4.5

article thumbnail

Centanafadine Study: New ADHD Drug Effective for Adults and Kids

ADDitude

Abstract presented at: Psych Congress 2024; October 29 to November 2, 2024; Boston, MA. Efficacy and safety of once-daily extended-release centanafadine for the treatment of attention-deficit/hyperactivity disorder in pediatric patients. Poster #149. 3 Mohammadi, M. R., & Akhondzadeh, S.

article thumbnail

99 Pubs and Zero Followers? Psychiatric Leadership in the Age of Influencers

Psychiatric Times

October 19, 2024. September 3, 2024. October 19, 2024. June 25, 2024. March 18, 2024. July 10, 2024. Gaslighting, narcissist, and more psychology terms you're misusing. March 15, 2023. Accessed April 10, 2025. When therapy goes wrong: the problem of underqualified psychotherapists. The Guardian.